Pune, Feb. 15, 2024 (GLOBE NEWSWIRE) -- According to the latest report published by Growth Plus Reports, the global Non-steroidal Anti-inflammatory Drug Market is expected to clock US$ 24.13 billion by 2031 and to grow at a CAGR of 5.27% during the forecast period.
The global Non-Steroidal Anti-Inflammatory Drug (NSAID) Market is experiencing steady growth, driven by the increasing prevalence of musculoskeletal disorders, inflammatory conditions, and pain-related ailments worldwide. With a focus on pain management, inflammation reduction, and improved patient outcomes, NSAIDs play a crucial role in the pharmacological treatment of various acute and chronic conditions.
Get a Sample Copy of the Research Report: https://www.growthplusreports.com/inquiry/request-sample/non-steroidal-antiinflammatory-drug-market/8528
Non-steroidal Anti-inflammatory Drug Market Scope
| Report Attribute | Details |
| Market Size Value in 2022 | US$ 19.51 billion |
| Revenue Forecast in 2031 | US$ 24.13 billion |
| CAGR | 5.27% |
| Base Year for Estimation | 2022 |
| Forecast Period | 2023-2031 |
| Historical Year | 2021 |
| Segments Covered | Application, Route of Administration, Distribution Channel, and Region |
| Regional Scope | North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
Market Overview:
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) are a class of medications commonly used to relieve pain, reduce inflammation, and lower fever. These drugs work by inhibiting the activity of cyclooxygenase (COX) enzymes, thereby blocking the production of prostaglandins, which are responsible for mediating pain and inflammation responses in the body. NSAIDs are widely available over-the-counter (OTC) or as prescription medications and are used to treat a variety of conditions, including arthritis, headache, menstrual cramps, and acute injuries.
Key Market Drivers:
- Rising Incidence of Musculoskeletal Disorders: Musculoskeletal disorders, such as osteoarthritis, rheumatoid arthritis, and low back pain, represent a significant burden on global healthcare systems, affecting millions of individuals worldwide. The increasing prevalence of these conditions, coupled with the aging population and sedentary lifestyles, drives the demand for NSAIDs as first-line pharmacological therapy for pain relief and symptom management.
- Growing Awareness of Pain Management: With a greater emphasis on pain assessment, patient-centered care, and multidisciplinary approaches to pain management, healthcare providers are increasingly prescribing NSAIDs to alleviate pain and improve quality of life for patients. NSAIDs offer effective relief from acute and chronic pain, allowing individuals to engage in daily activities, participate in rehabilitation programs, and enhance overall well-being.
- Expanding Indications and Formulations: The versatility of NSAIDs in treating a wide range of inflammatory conditions and pain syndromes has led to the development of new formulations, combination therapies, and targeted delivery systems. Pharmaceutical companies are investing in research and development to innovate NSAID formulations with improved efficacy, safety profiles, and patient convenience, driving market growth and product differentiation.
Competitive Landscape:
The Non-Steroidal Anti-Inflammatory Drug Market features a competitive landscape with key players focusing on product innovation, strategic partnerships, and geographical expansion to gain a competitive edge. Companies invest in research and development to develop new formulations, improve drug delivery systems, and address unmet medical needs in pain management and inflammation control.
Challenges and Opportunities:
While the Non-Steroidal Anti-Inflammatory Drug Market presents significant opportunities for growth and innovation, challenges such as gastrointestinal and cardiovascular risks, regulatory compliance, and generic competition need to be addressed. However, ongoing advancements in drug discovery, personalized medicine, and pharmacogenomics offer opportunities to develop safer, more effective NSAID therapies tailored to individual patient needs.
Table of Content
- INTRODUCTION
- Market Ecosystem
- Timeline Under Consideration
- Historical Years – 2021
- Base Year – 2022
- Forecasted Years – 2023 to 2031
- Currency Used in the Report
- RESEARCH METHODOLOGY
- Research Approach
- Data Collection Methodology
- Data Sources
- Secondary Sources
- Primary Sources
- Market Estimation Approach
- Bottom Up
- Top Down
- Market Forecasting Model
- Limitations and Assumptions
- PREMIUM INSIGHTS
- Current Market Trends (COVID-19 Perspective)
- Key Players & Competitive Positioning (2022)
- MARKET DYNAMICS
- Drivers
- Restraints
- Opportunities
- GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUG MARKET- ANALYSIS & FORECAST, BY APPLICATION
- Arthritis
- Ophthalmic Diseases
- Migraine
- Others
- GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUG MARKET- ANALYSIS & FORECAST, BY ROUTE OF ADMINISTRATION
- Oral
- Parenteral
- GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUG MARKET- ANALYSIS & FORECAST, BY DISTRIBUTION CHANNEL
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
Future Outlook:
The Non-Steroidal Anti-Inflammatory Drug Market is poised for continued growth, driven by the increasing demand for pain relief, inflammation management, and improved quality of life for patients with musculoskeletal and inflammatory conditions. As healthcare providers adopt evidence-based approaches to pain management and personalized medicine, NSAIDs will continue to play a central role in multimodal treatment regimens, offering safe and effective options for patients worldwide.
In conclusion, the Non-Steroidal Anti-Inflammatory Drug Market represents a vital segment within the pharmaceutical industry, addressing the diverse needs of patients suffering from pain and inflammation. By investing in research, innovation, and patient-centered care, stakeholders can advance the field of pain management, enhance treatment outcomes, and alleviate the burden of musculoskeletal disorders and inflammatory diseases on global health.
VALUE PROPOSITIONS RELATED TO THE REPORT:
- Powered with Complimentary Analyst Hours and Expert Interviews with Each Report
- Comprehensive quantitative and qualitative insights at segment and sub-segment level
- Covid 19 impact trends and perspective
- Granular insights at global/regional/country level
- Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment
- Blanket coverage on competitive landscape
- Winning imperatives
- Exhaustive coverage on 'Strategic Developments' registered by leading players of the market
CUSTOMIZATION OPTIONS:
- Distributor Landscape Assessment
- Pricing Intelligence
- Customer Base Assessment
- Investment & Initiatives Analysis
- 'Business Profile' of Key Players
Buy this Premium Research Report: https://www.growthplusreports.com/checkout-8528
Browse other reports:
The global Salmonella treatment market is expected to register a revenue CAGR of 7.3% during the forecast period from 2022 to 2030.
According to the deep-dive market assessment study by Growth Plus Reports, the global scoliosis management market was valued at US$ 2.2 billion in 2021 and is expected to register a revenue CAGR of 4.3% to reach US$ 3.21 billion by 2030.
According to the deep-dive market assessment study by Growth Plus Reports, the global sterilization indicator tape market was valued at US$ 121 million in 2021 and is expected to register a revenue CAGR of 3.8% to reach US$ 169.26 million by 2030.
According to the deep-dive market assessment study by Growth Plus Reports, the global surgical drill market was valued at US$ 1.2 billion in 2021 and is expected to register a revenue CAGR of 6.1% to reach US$ 2.04 billion by 2030.
Based on the deep-dive market assessment study by Growth Plus Reports, the global Whole exome sequencing market was valued at US$ 1.02 billion in 2021 and is expected to register a revenue CAGR of 18.70% to reach US$ 4.80 billion by 2030.
About Us:
Growth Plus Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).
Growth Plus portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success.
We were awarded by the prestigious CEO Magazine as "Most Innovative Healthcare Market Research Company in 2020.
